A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation
M. W. Bahar, V. Nasta, H. Fox, L. Sherry, K. Grehan, C. Porta, A. J. Macadam, N. J. Stonehouse, D. J. Rowlands, E. E. Fry, D. I. Stuart
Abstract
Strategies to prevent the recurrence of poliovirus (PV) after eradication may utilise non-infectious, recombinant virus-like particle (VLP) vaccines. Despite clear advantages over inactivated or attenuated virus vaccines, instability of VLPs can compromise their immunogenicity. Glutathione (GSH), an important cellular reducing agent, is a crucial co-factor for the morphogenesis of enteroviruses, including PV. We report cryo-EM structures of GSH bound to PV serotype 3 VLPs showing that it can enhance particle stability. GSH binds the positively charged pocket at the interprotomer interface shown recently to bind GSH in enterovirus F3 and putative antiviral benzene sulphonamide compounds in other enteroviruses. We show, using high-resolution cryo-EM, the binding of a benzene sulphonamide compound with a PV serotype 2 VLP, consistent with antiviral activity through over-stabilizing the interprotomer pocket, preventing the capsid rearrangements necessary for viral infection. Collectively, these results suggest GSH or an analogous tight-binding antiviral offers the potential for stabilizing VLP vaccines.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Use of a glycan library reveals a new model for enteric virus oligosaccharide binding and virion stabilization
H. Lu, M. A. Lehrman, J. K. Pfeiffer·bioRxiv·Nov 7, 2019
- Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particles
Lee Sherry, Mohammad W. Bahar, … David J. Rowlands·Nature CommunicationsPeer-reviewed·Jan 18, 2025
- Production and characterisation of stabilised PV-3 virus-like particles using Pichia pastoris
L. Sherry, K. Grehan, … N. J. Stonehouse·bioRxiv·Sep 16, 2022
- Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability
P. J. M. Brouwer, A. Antanasijevic, … R. W. Sanders·bioRxiv·Mar 28, 2022
- Upscaling production of immunogenic poliovirus virus-like particles in Pichia Pastoris by controlled fermentation
Lee Sherry, Keith Grehan, … Nicola J. Stonehouse·npj VaccinesPeer-reviewed·Mar 31, 2025
- Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate.
N. J. Kingston, J. S. Snowden, … N. J. Stonehouse·bioRxiv·Jan 30, 2023